Latest Insider Transactions at Harpoon Therapeutics, Inc. (HARP)
This section provides a real-time view of insider transactions for Harpoon Therapeutics, Inc. (HARP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Harpoon Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Harpoon Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 02
2021
|
Mpm Bio Ventures 2014, L.P. |
SELL
Open market or private sale
|
Indirect |
48,421
-1.33%
|
$968,420
$20.13 P/Share
|
|
Jan 27
2021
|
Mpm Bio Ventures 2014, L.P. |
SELL
Open market or private sale
|
Indirect |
706,825
-16.29%
|
$14,136,500
$20.0 P/Share
|
|
Jan 26
2021
|
Mpm Bio Ventures 2014, L.P. |
SELL
Open market or private sale
|
Indirect |
1,363
-0.03%
|
$28,623
$21.08 P/Share
|
|
Jan 25
2021
|
Mpm Bio Ventures 2014, L.P. |
SELL
Open market or private sale
|
Indirect |
13,006
-0.3%
|
$273,126
$21.23 P/Share
|
|
Jan 22
2021
|
Mpm Bio Ventures 2014, L.P. |
SELL
Open market or private sale
|
Indirect |
24,695
-0.56%
|
$518,595
$21.72 P/Share
|
|
Jan 21
2021
|
Mpm Bio Ventures 2014, L.P. |
SELL
Open market or private sale
|
Indirect |
26,066
-0.2%
|
$573,452
$22.83 P/Share
|
|
Jan 20
2021
|
Mpm Bio Ventures 2014, L.P. |
SELL
Other acquisition or disposition
|
Indirect |
101,646
-2.26%
|
-
|
|
Jan 20
2021
|
Mpm Bio Ventures 2014, L.P. |
SELL
Open market or private sale
|
Indirect |
17,694
-0.2%
|
$424,656
$24.33 P/Share
|
|
Jan 11
2021
|
Ronald Hunt |
BUY
Open market or private purchase
|
Indirect |
235,294
+20.48%
|
$3,999,998
$17.0 P/Share
|
|
Jan 11
2021
|
New Leaf Ventures Iii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
235,294
+20.48%
|
$3,999,998
$17.0 P/Share
|
|
Jan 04
2021
|
Holger Wesche Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-5.61%
|
$180,000
$18.34 P/Share
|
|
Jan 04
2021
|
Holger Wesche Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+13.73%
|
$0
$0.6 P/Share
|
|
Oct 01
2020
|
Holger Wesche Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-8.11%
|
$160,000
$16.61 P/Share
|
|
Oct 01
2020
|
Holger Wesche Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+13.76%
|
$0
$0.6 P/Share
|
|
Feb 12
2019
|
Mpm Bio Ventures 2014, L.P. |
BUY
Open market or private purchase
|
Indirect |
250,000
+5.24%
|
$3,500,000
$14.0 P/Share
|
|
Feb 12
2019
|
Mpm Bio Ventures 2014, L.P. |
SELL
Open market or private sale
|
Indirect |
1,524
-0.04%
|
$21,336
$14.0 P/Share
|
|
Feb 12
2019
|
Mpm Bio Ventures 2014, L.P. |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
432,119
+9.18%
|
$0
$0.05 P/Share
|
|
Feb 12
2019
|
Mpm Bio Ventures 2014, L.P. |
BUY
Conversion of derivative security
|
Indirect |
3,521,767
+28.86%
|
-
|
|
Feb 12
2019
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
250,000
+6.03%
|
$3,500,000
$14.0 P/Share
|
|
Feb 12
2019
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
447
-0.01%
|
$6,258
$14.0 P/Share
|
|
Feb 12
2019
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
127,096
+3.37%
|
$0
$0.05 P/Share
|
|
Feb 12
2019
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
3,521,773
+31.44%
|
-
|